Angiogenesis and the growth potential of craniopharyngiomas

Endocrine Pathology

Volumn 16, Issue 3, 2005, Pages 219-228

  Vidal, Sergio ^a,c   Scheithauer, Bernd W ^b   Kovacs, Kalman ^b   Lloyd, Ricardo V ^b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Angiogenesis; Cell proliferation; Craniopharyngioma; Integrin v 3; Microvessel density (MVD)

Indexed keywords

ALPHA INTEGRIN; CD34 ANTIGEN; CELL MARKER; KI 67 ANTIGEN; VITRONECTIN RECEPTOR;

ADOLESCENT; ADULT; AMELOBLASTOMA; ANGIOGENESIS; ARTICLE; CANCER GROWTH; CELL MIGRATION; CELL NUCLEUS; CELL PROLIFERATION; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; CRANIOPHARYNGIOMA; DENSITY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROVASCULATURE; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA; TUMOR CELL;

ADOLESCENT; ANTIGENS, CD34; CELL COUNT; CHILD; CHILD, PRESCHOOL; CRANIOPHARYNGIOMA; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; INTEGRIN ALPHAVBETA3; KI-67 ANTIGEN; MALE; MICROCIRCULATION; NEOVASCULARIZATION, PATHOLOGIC; PITUITARY NEOPLASMS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 28044453327     PISSN: 10463976     EISSN: None     Source Type: Journal    
DOI: 10.1385/EP:16:3:219     Document Type: Article

References (49)

1. Grotzer MA, Wiewrodt R, Janss AJ, et al. High microvessel density in primitive neuroectodermal brain tumors of childhood. Neuropediatrics 32(2):75-79, 2001.
2. Leon SP, Folkerth RD, Black PM. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 77(2):362-372, 1996.
3. Assimakopoulou M, Sotiropoulou-Bonikou G, Maraziotis T, Papadakis N, Varakis I. Microvessel density in brain tumors. Anticancer Res 17(6D):4747-4753, 1997.
4. Brat DJ, Castellano-Sanchez A, Kaur B, Van Meir EG. Genetic and biologic progression in astrocytomas and their relation to angiogenic dysregulation. Adv Anat Pathol 9(1):24-36, 2002.
5. Germano A, Caffo M, Caruso G, La Rosa G, Galatioto S, Tomasello F. A preliminary study of angiogenesis in paediatric glioblastoma multiforme and its correlation with survival. Childs Nerv Syst 17(10):577-583, 2001.
6. Chaudhry IH, O'Donovan DG, Brenchley PE, Reid H, Roberts IS. Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. Histopathology 39(4):409-415, 2001.
7. Kleihues P, Burger PC, Collins VP. Glioblastomas. In Kleihues P, Cavanee WK, eds. World Health Organization Classification of Tumors. Pathology and Genetics. Tumours of the nervous system. Lyon: IARC Press, 2000, pp. 29-39.
8. Vidal S, Kovacs K, Lloyd RV, Meyer FB, Scheithauer BW. Angiogenesis in patients with craniopharyngiomas: correlation with treatment and outcome. Cancer 94(3):738-745, 2002.
9. Elmaci L, Kurtkaya-Yapicier O, Ekinci G, et al. Metastatic papillary craniopharyngioma: case study and study of tumor angiogenesis. Neuro-oncol 4(2):123-128, 2002.
10. Isaac MA, Hahn SS, Kim JA, Bogart JA, Chung CT. Management of craniopharyngioma. Cancer J 7(6):516-520, 2001.
11. Habrand JL, Ganry O, Couanet D, et al. The role of radiation therapy in the management of craniopharyngioma: a 25-year experience and review of the literature. Int J Radiat Oncol Biol Phys 44(2):255-263, 1999.
12. Hader WJ, Steinbok P, Hukin J, Fryer C. Intratumoral therapy with bleomycin for cystic craniopharyngiomas in children. Pediatr Neurosurg 33(4):211-218, 2000.
13. Brandes AA, Basso U, Pasetto LM, Ermani M. New strategy developments in brain tumor therapy. Curr Pharm Des 7(16):1553-1580, 2001.
14. Kunkel P, Ulbricht U, Bohlen P, et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 61(18):6624-6628, 2001.
15. Bello L, Lucini V, Carrabba G, et al. Simultaneous inhibition of glioma angiogenesis, cell proliferation, and invasion by a naturally occurring fragment of human metalloproteinase-2. Cancer Res 61(24):8730-8736, 2001.
16. Peroulis I, Jonas N, Saleh M. Antiangiogenic activity of endostatin inhibits C6 glioma growth. Int J Cancer 97(6):839-845, 2002.
17. Vidal S, Kovacs K, Horvath E, Scheithauer BW, Kuroki T, Lloyd RV. Microvessel density in pituitary adenomas and carcinomas. Virchows Arch 438(6):595-602, 2001.
18. Thapar K, Kovacs K, Scheithauer BW, et al. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38(1):99-106; discussion 106-107, 1996.
19. Vidal S, Roman A, Moya L, Kovacs K. Expression of 3 beta-hydroxysteroid dehydrogenase/isomerase in the female rat pituitary. J Endocrinol 166(1):95-101, 2000.
20. Sanno N, Teramoto A, Osamura R. Tyramide amplification in immunohistochemistry. In Lloyd RV, ed. Morphology methods: cell and molecular biology techniques. Totowa, NJ: Humana Press, 2001; pp. 267-276.
21. vβ5 involves ceramide metabolic pathways. Blood 105(11):4353-4361, 2005.
22. Brooks PC, Montgomery AM, Rosenfeld M, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79(7):1157-1164, 1994.
23. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64(2):327-336, 1991.
24. Izycka-Swieszewska E, Rzepko R, Borowska-Lehman J, Baranowska E, Warzocha D. Recurrent meningiomas - the immunohistochemical analysis of angiogenesis and cellular proliferation. Preliminary study. Folia Neuropathol 37(3):179-184, 1999.
25. Abdalla SA, Behzad F, Bsharah S, et al. Prognostic relevance of microvessel density in colorectal tumours. Oncol Rep 6(4):839-842, 1999.
26. Barker FG, 2nd, Davis RL, Chang SM, Prados MD. Necrosis as a prognostic factor in glioblastoma multiforme. Cancer 77(6):1161-1166, 1996.
27. Siitonen SM, Haapasalo HK, Rantala IS, Helin HJ, Isola JJ. Comparison of different immunohistochemical methods in the assessment of angiogenesis: lack of prognostic value in a group of 77 selected node-negative breast carcinomas. Mod Pathol 8(7):745-752, 1995.
28. Vidal S, Horvath E, Kovacs K, Lloyd RV, Scheithauer BW. Microvascular structural entropy: a novel approach to assess angiogenesis in pituitary tumors. Endocr Pathol 14(3):239-247, 2003.
29. Salvesen HB, Iversen OE, Akslen LA. Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study. J Clin Oncol 17(5):1382-1390, 1999.
30. Vaquero J, Zurita M, de Oya S, Coca S, Morales C, Salas C. Expression of vascular permeability factor in craniopharyngioma. J Neurosurg 91(5):831-834, 1999.
31. Duo D, Gasverde S, Benech F, Zenga F, Giordana MT. MIB-1 immunoreactivity in craniopharyngiomas: a clinico-pathological analysis. Clin Neuropathol 22(5):229-234, 2003.
32. Losa M, Vimercati A, Acerno S, et al. Correlation between clinical characteristics and proliferative activity in patients with craniopharyngioma. J Neurol Neurosurg Psychiatry 75(6):889-892, 2004.
33. Nishi T, Kuratsu J, Takeshima H, Saito Y, Kochi M, Ushio Y. Prognostic significance of the MIB-1 labeling index for patient with craniopharyngioma. Int J Mol Med 3 (2):157-161, 1999.
34. Kim SK, Wang KC, Shin SH, Choe G, Chi JG, Cho BK. Radical excision of pediatric craniopharyngioma: recurrence pattern and prognostic factors. Childs Nerv Syst 17(9):531-536; discussion 537, 2001.
35. Raghavan R, Dickey WT, Jr., Margraf LR, et al. Proliferative activity in craniopharyngiomas: clinicopathological correlations in adults and children. Surg Neurol 54(3):241-247; discussion 248, 2000.
36. Madhusudan S, Harris AL. Drug inhibition of angiogenesis. Curr Opin Pharmacol 2(4):403-414, 2002.
37. vβ3 for angiogenesis. Science 264(5158):569-571, 1994.
38. Hood JD, Bednarski M, Frausto R, et al. Tumor regression by targeted gene delivery to the neovasculature. Science 296(5577):2404-2407, 2002.
39. Kumar CC, Malkowski M, Yin Z, et al. Inhibition of angiogenesis and tumor growth by SCH221153, a dual α(v)β3 and γ(v)β5 integrin receptor antagonist. Cancer Res 61(5):2232-2238, 2001.
40. Kumar CC, Armstrong L, Yin Z, et al. Targeting integrins αvβ3 and αvβ5 for blocking tumor-induced angiogenesis. Adv Exp Med Biol 476:169-180, 2000.
41. Reynolds LE, Wyder L, Lively JC, et al. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med 8(1):27-34, 2002.
42. Bello L, Francolini M, Marthyn P, et al. α(v)β3 and α(v)β5 integrin expression in glioma periphery. Neurosurgery 49(2):380-389; discussion 390, 2001.
43. Pazouki S, Chisholm DM, Adi MM, et al. The association between tumour progression and vascularity in the oral mucosa. J Pathol 183(1):39-43, 1997.
44. Gasparini G, Brooks PC, Biganzoli E, et al. Vascular integrin α(v)β3: a new prognostic indicator in breast cancer. Clin Cancer Res 4(11):2625-2634, 1998.
45. Vonlaufen A, Wiedle G, Borisch B, Birrer S, Luder P, Imhof BA. Integrin α(v)β(3) expression in colon carcinoma correlates with survival. Mod Pathol 14(11):1126-1132, 2001.
46. Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85(3):221-228, 1999.
47. Asahara T, Isner JM. Endothelial progenitor cells for vascular regeneration. J Hematother Stem Cell Res 11(2):171-178, 2002.
48. Vartanian RK, Weidner N. Endothelial cell proliferation in prostatic carcinoma and prostatic hyperplasia: correlation with Gleason's score, microvessel density, and epithelial cell proliferation. Lab Invest 73(6):844-850, 1995.
49. Vermeulen PB, Verhoeven D, Hubens G, et al. Microvessel density, endothelial cell proliferation and tumour cell proliferation in human colorectal adenocarcinomas. Ann Oncol 6(1):59-64, 1995.